Cryopal S.A.S.

Cryopal S. A. S. is a French company specializing in innovative cryogenic storage solutions, including systems for liquid oxygen therapy and biological material preservation, primarily catering to the healthcare sector.

Founded in 1968 in France, Cryopal S. A. S. provides cryogenic storage solutions for healthcare applications.

In December 2022, the company was acquired by Initiative & Finance and its management from Air Liquide. The founder's history is not publicly available, and there are no known pivots or subsidiaries mentioned. The company has engaged in a total of 1 deal, with the most recent deal occurring on December 1, 2022, in France. Cryopal specializes in providing innovative cryogenic storage solutions, including liquid oxygen therapy systems for home use, cryogenic sample preservation in liquid or gaseous nitrogen, and transportation solutions for maintaining cryogenic temperatures.

Their products are designed to ensure the safe storage and transfer of biological materials, catering primarily to the healthcare sector, including hospitals, research laboratories, and patients with respiratory conditions. With over 55 years of experience, Cryopal's products have been released into multiple international markets, servicing more than 90 countries worldwide. The company also offers custom services, such as designing cryopreservation rooms, which further solidifies its commitment to addressing the unique needs of its diverse client base. Cryopal’s revenue model centers around direct sales of its flagship products, including cryogenic storage tanks and oxygen therapy systems, to healthcare providers and institutions.

The company engages in B2B transactions, where clients may purchase these products outright or enter into service agreements for ongoing maintenance and support. Additionally, partnerships with healthcare facilities could provide a recurring revenue stream through subscription-based models for product servicing and supply. The specific pricing structure for these products is determined based on the comprehensive needs of each client, ensuring that solutions are tailored to their operational requirements and budgetary considerations. Following its acquisition in December 2022, Cryopal plans to expand its research and development capacities and production tools, focusing on enhancing service offerings in both European and international markets.

The investment will support the introduction of upcoming products and services designed to meet the evolving needs of the healthcare sector. Specific markets targeted for expansion have not been disclosed, but the company aims to leverage its enhanced capabilities to increase its footprint globally.